Carl H Sadowsky

Carl H Sadowsky

UNVERIFIED PROFILE

Are you Carl H Sadowsky?   Register this Author

Register author
Carl H Sadowsky

Carl H Sadowsky

Publications by authors named "Carl H Sadowsky"

Are you Carl H Sadowsky?   Register this Author

30Publications

762Reads

37Profile Views

Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.

Alzheimer Dis Assoc Disord 2015 Jul-Sep;29(3):192-9

*AbbVie Inc., North Chicago, IL †Berry Consultants, LLC, Austin, TX ‡MD Anderson Cancer Center, University of Texas, Houston, TX §Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL ∥Palm Beach Neurology, West Palm Beach, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WAD.0000000000000093DOI Listing
August 2016

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.

Alzheimer Dis Assoc Disord 2015 Apr-Jun;29(2):110-6

*Department of Neurology, Indiana University School of Medicine, Indianapolis, IN †Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, MO ‡Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL §Novartis Pharmaceuticals Corporation, East Hanover, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WAD.0000000000000073DOI Listing
February 2016

Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.

CNS Neurosci Ther 2015 Jun 10;21(6):513-9. Epub 2015 Feb 10.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cns.12385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6495641PMC
June 2015

Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.

Prim Care Companion CNS Disord 2014 4;16(5). Epub 2014 Sep 4.

Division of Neurology, Nova Southeastern University, Fort Lauderdale, and Premiere Research Institute, Palm Beach Neurology, West Palm Beach, Florida (Dr Sadowsky); Private Practice, Marietta, Georgia (Dr Micca); Department of Neurology and Psychiatry, St Louis University School of Medicine, St Louis, Missouri (Dr Grossberg); and Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Dr Velting).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.14r01654DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321018PMC
February 2015

Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.

J Neuropathol Exp Neurol 2014 Jan;73(1):72-80

From the Avid Radiopharmaceuticals (CMC, ML, APC, ADJ, MAM, MJP, DMS), Philadelphia, Pennsylvania; Banner Sun Health Research Institute (BND, GS, MM, MNS, LIS, TGB), Sun City, Arizona; Biospective Inc. and Montreal Neurological Institute (BJB, SPZ), McGill University, Montreal, Canada; Duke University Medical Center (REC, PMD), Durham, North Carolina; Banner Alzheimer's Institute (ASF, EMR), Phoenix, Arizona; Nova SE University (CHS), Ft Lauderdale, Florida; and Rush University Medical Center (JAS), Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NEN.0000000000000028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037918PMC
January 2014

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.

CNS Neurosci Ther 2013 Oct 7;19(10):745-52. Epub 2013 Aug 7.

Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cns.12158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233957PMC
October 2013

Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.

Prim Care Companion CNS Disord 2011 ;13(3)

Division of Neurology, Nova SE University, Fort Lauderdale, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.10m01101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184571PMC
June 2013

Guidelines for the management of cognitive and behavioral problems in dementia.

J Am Board Fam Med 2012 May-Jun;25(3):350-66

Division of Neurology, Nova Southeastern University, Fort Lauderdale, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3122/jabfm.2012.03.100183DOI Listing
September 2012

Practical guidelines for the recognition and diagnosis of dementia.

J Am Board Fam Med 2012 May-Jun;25(3):367-82

Center of Excellence for Brain Aging, New York University Langone School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3122/jabfm.2012.03.100181DOI Listing
September 2012

Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.

Headache 2012 Sep 18;52(8):1219-25. Epub 2012 May 18.

Palm Beach Headache Center, West Palm Beach, FL 33407, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1526-4610.2012.02164.xDOI Listing
September 2012

Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results.

Prim Care Companion J Clin Psychiatry 2010 ;12(5)

Nova SE University, Fort Lauderdale, and Premiere Research Institute, Palm Beach Neurology, West Palm Beach, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/PCC.09m00852oliDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025991PMC
November 2011

Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease.

Am J Alzheimers Dis Other Demen 2009 Jun-Jul;24(3):267-75. Epub 2009 Mar 16.

Nova SE University, Fort Lauderdale, Florida, USA.

View Article

Download full-text PDF

Source
http://aja.sagepub.com/content/24/3/267.full.pdf
Web Search
http://aja.sagepub.com/cgi/doi/10.1177/1533317509333037
Publisher Site
http://dx.doi.org/10.1177/1533317509333037DOI Listing
October 2009

The validation of a caregiver assessment of dementia: the Dementia Severity Scale.

Alzheimer Dis Assoc Disord 2005 Oct-Dec;19(4):186-94

Mt. Sinai School of Medicine, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
March 2006

Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.

Prim Care Companion J Clin Psychiatry 2005 ;7(2):43-48

Department of Neurology, Nova Southeastern University, Fort Lauderdale, Fla. ; Department of Neurology, Indiana University School of Medicine, Indianapolis, Ind. ; and Novartis Pharmaceuticals Corporation, East Hanover, N.J.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1079694PMC
http://dx.doi.org/10.4088/pcc.v07n0201DOI Listing
January 2005